Pharmacodynamics of dalbavancin studied in an in vitro pharmacokinetic system

被引:30
作者
Bowker, Karen E.
Noel, Alan R.
MacGowan, Alasdair P.
机构
[1] N Bristol NHS Trust, Bristol Ctr Antimicrobial Res & Evaluat, Bristol, Avon, England
[2] Univ Bristol, Bristol, Avon, England
关键词
AUC/MIC; S; aureus; VISA;
D O I
10.1093/jac/dkl311
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: The antibacterial effect of dalbavancin was studied against Staphylococcus aureus using stepwise declining concentrations designed to model a range of free drug concentrations observed in human serum. Methods: Initial concentrations ranged from 0.6 to 21 mg/L and experiments were conducted over 240 h. Three vancomycin-susceptible and one vancomycin-intermediate strain of S. aureus were used. Results and conclusions: Dalbavancin showed non-concentration-dependent killing against the three vancomycin-susceptible strains in the range 3-21 mg/L and the vancomycin-intermediate strain at 15 and 21 mg/L. AUC/MIC could be related to antibacterial effect. The AUC/MIC for a bacteriostatic effect was 36 at 24 h, 55 at 120 h and 100 at 240 h. A larger AUC/MIC was required to produce a 2 log reduction in counts, being 214 at 24 h, 195 at 120 h and 331 at 240 h.
引用
收藏
页码:802 / 805
页数:4
相关论文
共 13 条
[1]  
[Anonymous], 1999, CLIN ANTIMICROBIAL A
[2]  
[Anonymous], 1999, J ANTIMICROB CHEMOTH
[3]  
[Anonymous], 1999, CLIN ANTIMICROBIAL A
[4]   QUESTIONING DOSING REGIMENS OF CIPROFLOXACIN [J].
BAUERNFEIND, A .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1993, 31 (05) :789-798
[5]   In-vitro and in-vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic [J].
Candiani, G ;
Abbondi, M ;
Borgonovi, M ;
Romanò, G ;
Parenti, F .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 44 (02) :179-192
[6]  
DOWELL J, 2003, CLIN MICROBIOL INFEC, V9, P291
[7]   Efficacy of dalbavancin against methicillin-resistant Staphylococcus aureus in the rat granuloma pouch infection model [J].
Jabés, D ;
Candiani, G ;
Romanó, G ;
Brunati, C ;
Riva, S ;
Cavaleri, M .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (04) :1118-1123
[8]   Antistaphylococcal activity of dalbavancin, an experimental glycopeptide [J].
Lin, G ;
Credito, K ;
Ednie, LM ;
Appelbaum, PC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (02) :770-772
[9]   Developments in PK/PD: optimising efficacy and prevention of resistance. A critical review of PK/PD in in vitro models [J].
MacGowan, A ;
Bowker, K .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2002, 19 (04) :291-298
[10]   Effect of ertapenem protein binding on killing of bacteria [J].
Nix, DE ;
Matthias, KR ;
Ferguson, EC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (09) :3419-3424